TABLE 2 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens
Year: 2023
Type: other
Abstract: Treatment-emergent adverse events in cohorts Q2W-LD and Q3W (all-treated/safety population)
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4386225177